The FDA hit Indian API manufacturer Alchymars ICM SM with a warning letter after an investigation found the firm falsified laboratory data, failed to thoroughly investigate complaints and improperly maintained equipment and facilities at its Chennai, Tamil Nadu facility.
Source: Drug Industry Daily